Margaretha G. M. Roemer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Margaretha G. M. Roemer has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Bauke Ylstra
Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
22 shared publications - Daphne de Jong
HOVON Pathology Facility and Biobank (HOP), Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
22 shared publications - G. Tjitske Los-De Vries
Amsterdam UMC-Vrije Universiteit Amsterdam, Department of Pathology and Cancer Center Amsterdam, Amsterdam, The Netherlands
21 shared publications - Phylicia Stathi
Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands
21 shared publications - Jeroen A.C.W. Luijks
Department of Pathology, Radboud university medical center
19 shared publications - Nathalie J. Hijmering
Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands
19 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Wiley in JIMD Reports
- Vol. 67 (6) , e70128
Alder–Reilly Anomaly Leading to Incidental Diagnosis of MPS VII in an Asymptomatic Adult
Mucopolysaccharidosis type VII (MPS VII; Sly syndrome) is a rare autosomal recessive lysosomal storage disorder caused by deficiency of β‐glucuronidase due to pathogenic variants in the GUSB gene. Impaired degradation of glycosaminoglycans (GAGs) results in multiorgan dysfunction with highly variable clinical presentation, ranging from severe neonatal disease to attenuated adult phenotypes. We report an incidental diagnosis of MPS VII in a 31‐year‐old woman identified through routine laboratory testing. Review of a peripheral blood smear was prompted by automated hematology analyzer flags and revealed Alder–Reilly anomaly with characteristic aberrant leukocyte granulation. Subsequent biochemical analysis showed elevated urinary dermatan sulfate and heparan sulfate, alongside reduced β‐glucuronidase activity (~2%–3% of normal). Genetic testing of GUSB identified compound heterozygosity for a likely pathogenic frameshift variant (c.133_134del) and a missense variant (c.454G>A) previously associated with pseudodeficiency. Despite biochemical and genetic findings consistent with MPS VII, the patient exhibited no typical clinical manifestations, and detailed phenotyping showed no organ involvement. This case illustrates an atypical, asymptomatic presentation of MPS VII diagnosed in adulthood, in which Alder–Reilly anomaly served as a critical diagnostic clue. The combination of a null allele with a pseudodeficiency‐associated variant resulted in reduced enzyme activity without overt disease. These findings highlight the importance of peripheral blood smear evaluation in identifying lysosomal storage disorders and underscore the complexity of genotype–phenotype correlations in MPS VII.
- 22 October 2026
- Published by Wiley in JIMD Reports
- Vol. 67 (6) , e70128
Open AccessAlder–Reilly Anomaly Leading to Incidental Diagnosis of MPS VII in an Asymptomatic Adult
Mucopolysaccharidosis type VII (MPS VII; Sly syndrome) is a rare autosomal recessive lysosomal storage disorder caused by deficiency of β‐glucuronidase due to pathogenic variants in the GUSB gene. Impaired degradation of glycosaminoglycans (GAGs) results in multiorgan dysfunction with highly variable clinical presentation, ranging from severe neonatal disease to attenuated adult phenotypes. We report an incidental diagnosis of MPS VII in a 31‐year‐old woman identified through routine laboratory testing. Review of a peripheral blood smear was prompted by automated hematology analyzer flags and revealed Alder–Reilly anomaly with characteristic aberrant leukocyte granulation. Subsequent biochemical analysis showed elevated urinary dermatan sulfate and heparan sulfate, alongside reduced β‐glucuronidase activity (~2%–3% of normal). Genetic testing of GUSB identified compound heterozygosity for a likely pathogenic frameshift variant (c.133_134del) and a missense variant (c.454G>A) previously associated with pseudodeficiency. Despite biochemical and genetic findings consistent with MPS VII, the patient exhibited no typical clinical manifestations, and detailed phenotyping showed no organ involvement. This case illustrates an atypical, asymptomatic presentation of MPS VII diagnosed in adulthood, in which Alder–Reilly anomaly served as a critical diagnostic clue. The combination of a null allele with a pseudodeficiency‐associated variant resulted in reduced enzyme activity without overt disease. These findings highlight the importance of peripheral blood smear evaluation in identifying lysosomal storage disorders and underscore the complexity of genotype–phenotype correlations in MPS VII.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
Large B-cell lymphoma of immune-privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system (CNS). After initially reaching complete response, relapses occur in almost 50% of patients, typically at other immune-privileged sites. Resolution of the clonal relationships and evolutionary patterns of LBCL-IP is required to understand the unique clinical behavior. We collected a unique set of 33 primary–relapse LBCL-IP sample pairs and performed next-generation sequencing for copy number, mutation, translocation, and immunoglobulin clonality analysis. All LBCL-IP sample pairs were clonally related, and both tumors developed from a common progenitor cell (CPC) with MYD88 and TBL1XR1 mutations and/or BCL6 translocations in 30/33 cases, indicating that these are early genetic events. This was succeeded by intermediate genetic events including shared, as well as unique alterations in targets of aberrant somatic hypermutation (aSHM), CD79B mutations, and 9p21.3/CDKN2A loss. Genetic alterations in genes involved in immune escape (HLA, CD274/PDCD1LG2) were predominantly unique in primary and relapse samples and thus considered late genetic events. Together, this study indicates that primary and relapsed LBCL-IP follow an early parallel evolutionary pattern where the CPC contains genetic alterations that support prolonged survival/proliferation and retention in a memory B-cell state, followed by germinal center reentry, aSHM and immune escape.Significance:Genomic analyses reveal that primary and relapse LBCL-IP originate from a common progenitor cell with a small set of genetic alterations, followed by extensive parallel diversification, elucidating the clonal evolution of LBCL-IP.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
Large B-cell lymphoma of immune-privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system (CNS). After initially reaching complete response, relapses occur in almost 50% of patients, typically at other immune-privileged sites. Resolution of the clonal relationships and evolutionary patterns of LBCL-IP is required to understand the unique clinical behavior. We collected a unique set of 33 primary–relapse LBCL-IP sample pairs and performed next-generation sequencing for copy number, mutation, translocation, and immunoglobulin clonality analysis. All LBCL-IP sample pairs were clonally related, and both tumors developed from a common progenitor cell (CPC) with MYD88 and TBL1XR1 mutations and/or BCL6 translocations in 30/33 cases, indicating that these are early genetic events. This was succeeded by intermediate genetic events including shared, as well as unique alterations in targets of aberrant somatic hypermutation (aSHM), CD79B mutations, and 9p21.3/CDKN2A loss. Genetic alterations in genes involved in immune escape (HLA, CD274/PDCD1LG2) were predominantly unique in primary and relapse samples and thus considered late genetic events. Together, this study indicates that primary and relapsed LBCL-IP follow an early parallel evolutionary pattern where the CPC contains genetic alterations that support prolonged survival/proliferation and retention in a memory B-cell state, followed by germinal center reentry, aSHM and immune escape.Significance:Genomic analyses reveal that primary and relapse LBCL-IP originate from a common progenitor cell with a small set of genetic alterations, followed by extensive parallel diversification, elucidating the clonal evolution of LBCL-IP.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell
Supplementary Tables from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell
Supplementary Tables from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell
Supplementary Tables from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell
Supplementary Tables from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell
Large B-cell lymphoma of immune privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system. After initially reaching complete response, relapses occur in almost 50% of patients, typically at other immune privileged sites. Resolution of the clonal relationships and evolutionary patterns of LBCL-IP is required to understand the unique clinical behavior. We collected a unique set of 33 primary–relapse LBCL-IP sample pairs and performed next-generation sequencing for copy number, mutation, translocation and immunoglobulin clonality analysis. All LBCL-IP sample pairs were clonally related, and both tumors developed from a common progenitor cell (CPC) with MYD88 and TBL1XR1 mutations and/or BCL6 translocations in 30/33 cases, indicating that these are early genetic events. This was succeeded by intermediate genetic events including shared, as well as unique alterations in targets of aberrant somatic hypermutation (aSHM), CD79B mutations and 9p21.3/CDKN2A loss. Genetic alterations in genes involved in immune escape (HLA, CD274/PDL1LG2) were predominantly unique in primary and relapse samples and thus considered late genetic events. Together, this study indicates that primary and relapsed LBCL-IP follow an early parallel evolutionary pattern where the CPC contains genetic alterations that support prolonged survival/proliferation and retention in a memory B-cell state, followed by germinal center re-entry, aSHM and immune escape.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell
Large B-cell lymphoma of immune privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system. After initially reaching complete response, relapses occur in almost 50% of patients, typically at other immune privileged sites. Resolution of the clonal relationships and evolutionary patterns of LBCL-IP is required to understand the unique clinical behavior. We collected a unique set of 33 primary–relapse LBCL-IP sample pairs and performed next-generation sequencing for copy number, mutation, translocation and immunoglobulin clonality analysis. All LBCL-IP sample pairs were clonally related, and both tumors developed from a common progenitor cell (CPC) with MYD88 and TBL1XR1 mutations and/or BCL6 translocations in 30/33 cases, indicating that these are early genetic events. This was succeeded by intermediate genetic events including shared, as well as unique alterations in targets of aberrant somatic hypermutation (aSHM), CD79B mutations and 9p21.3/CDKN2A loss. Genetic alterations in genes involved in immune escape (HLA, CD274/PDL1LG2) were predominantly unique in primary and relapse samples and thus considered late genetic events. Together, this study indicates that primary and relapsed LBCL-IP follow an early parallel evolutionary pattern where the CPC contains genetic alterations that support prolonged survival/proliferation and retention in a memory B-cell state, followed by germinal center re-entry, aSHM and immune escape.
- Open Access
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
Supplementary Tables from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
Supplementary Tables from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell